http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 27 Jul 2026 09:08:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Sarepta+Therapeutics%2C+++++For%3A+Jul+23/26817088.html si-local-file:///var/storage/secattach/20260727/26817088.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Sarepta+Therapeutics%2C+++++For%3A+Jul+23/26817088.html Mon, 27 Jul 2026 09:08:00 -0400 O.00070249 SRPT http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Sarepta+Therapeutics%2C+++++For%3A+Jul+23/26817088.html si-local-file:///var/storage/secattach/20260727/26817088.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Sarepta+Therapeutics%2C+++++For%3A+Jul+23/26817088.html Mon, 27 Jul 2026 09:08:00 -0400 O.00070249 SRPT http://www.streetinsider.com/Management+Changes/Sarepta+Therapeutics+names+Michael+Severino+as+new+CEO/26816626.html <p>Sarepta Therapeutics (NASDAQ: SRPT) has appointed Michael Severino, M.D., as chief executive officer, effective July 28, 2026, according to a company statement. Severino will also join Sarepta's Board of Directors.</p><p>Severino succeeds Doug Ingram, who is retiring from the Cambridge, Mass.-based company. Ingram will remain in an advisory capacity through the end of 2026.</p><p>Severino most recently served as CEO of Tessera Therapeutics and as a CEO-Partner at Flagship Pioneering, roles he held since 2022. Before that, he was Vice Chairman and President at AbbVie, where he oversaw research and development and the corporate strategy office. His career also includes senior roles http://www.streetinsider.com/Management+Changes/Sarepta+Therapeutics+names+Michael+Severino+as+new+CEO/26816626.html Mon, 27 Jul 2026 08:30:47 -0400 SRPT http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html <p> – <b><i>Severino joins Sarepta’s Board of Directors</i></b> </p><p> – <b><i>Doug Ingram to retire from Sarepta</i></b> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition. </p><p> Severino brings more than 25 years of biopharmaceutical experience to Sarepta. Prior to http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html Mon, 27 Jul 2026 08:30:00 -0400 A.06145069 A.08435063 A.26342942 A.35954321 A.40221050 A.50216958 O.00070249 O.20032280 O.20042365 O.20737027 O.22095645 O.31241813 O.50070584 SRPT http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html <p> – <b><i>Severino joins Sarepta’s Board of Directors</i></b> </p><p> – <b><i>Doug Ingram to retire from Sarepta</i></b> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition. </p><p> Severino brings more than 25 years of biopharmaceutical experience to Sarepta. Prior to http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html Mon, 27 Jul 2026 08:30:00 -0400 A.06145069 A.08435063 A.26342942 A.35954321 A.40221050 A.50216958 O.00070249 O.20032280 O.20042365 O.20737027 O.22095645 O.31241813 O.50070584 SRPT http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html <p> – <b><i>Severino joins Sarepta’s Board of Directors</i></b> </p><p> – <b><i>Doug Ingram to retire from Sarepta</i></b> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition. </p><p> Severino brings more than 25 years of biopharmaceutical experience to Sarepta. Prior to http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html Mon, 27 Jul 2026 08:30:00 -0400 A.06145069 A.08435063 A.26342942 A.35954321 A.40221050 A.50216958 O.00070249 O.20032280 O.20042365 O.20737027 O.22095645 O.31241813 O.50070584 SRPT http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html <p> – <b><i>Severino joins Sarepta’s Board of Directors</i></b> </p><p> – <b><i>Doug Ingram to retire from Sarepta</i></b> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition. </p><p> Severino brings more than 25 years of biopharmaceutical experience to Sarepta. Prior to http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html Mon, 27 Jul 2026 08:30:00 -0400 A.06145069 A.08435063 A.26342942 A.35954321 A.40221050 A.50216958 O.00070249 O.20032280 O.20042365 O.20737027 O.22095645 O.31241813 O.50070584 SRPT http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html <p> – <b><i>Severino joins Sarepta’s Board of Directors</i></b> </p><p> – <b><i>Doug Ingram to retire from Sarepta</i></b> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition. </p><p> Severino brings more than 25 years of biopharmaceutical experience to Sarepta. Prior to http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html Mon, 27 Jul 2026 08:30:00 -0400 A.06145069 A.08435063 A.26342942 A.35954321 A.40221050 A.50216958 O.00070249 O.20032280 O.20042365 O.20737027 O.22095645 O.31241813 O.50070584 SRPT http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html <p> – <b><i>Severino joins Sarepta’s Board of Directors</i></b> </p><p> – <b><i>Doug Ingram to retire from Sarepta</i></b> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition. </p><p> Severino brings more than 25 years of biopharmaceutical experience to Sarepta. Prior to http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html Mon, 27 Jul 2026 08:30:00 -0400 A.06145069 A.08435063 A.26342942 A.35954321 A.40221050 A.50216958 O.00070249 O.20032280 O.20042365 O.20737027 O.22095645 O.31241813 O.50070584 SRPT http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html <p> – <b><i>Severino joins Sarepta’s Board of Directors</i></b> </p><p> – <b><i>Doug Ingram to retire from Sarepta</i></b> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition. </p><p> Severino brings more than 25 years of biopharmaceutical experience to Sarepta. Prior to http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html Mon, 27 Jul 2026 08:30:00 -0400 A.06145069 A.08435063 A.26342942 A.35954321 A.40221050 A.50216958 O.00070249 O.20032280 O.20042365 O.20737027 O.22095645 O.31241813 O.50070584 SRPT http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html <p> – <b><i>Severino joins Sarepta’s Board of Directors</i></b> </p><p> – <b><i>Doug Ingram to retire from Sarepta</i></b> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition. </p><p> Severino brings more than 25 years of biopharmaceutical experience to Sarepta. Prior to http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html Mon, 27 Jul 2026 08:30:00 -0400 A.06145069 A.08435063 A.26342942 A.35954321 A.40221050 A.50216958 O.00070249 O.20032280 O.20042365 O.20737027 O.22095645 O.31241813 O.50070584 SRPT http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html <p> – <b><i>Severino joins Sarepta’s Board of Directors</i></b> </p><p> – <b><i>Doug Ingram to retire from Sarepta</i></b> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition. </p><p> Severino brings more than 25 years of biopharmaceutical experience to Sarepta. Prior to http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html Mon, 27 Jul 2026 08:30:00 -0400 A.06145069 A.08435063 A.26342942 A.35954321 A.40221050 A.50216958 O.00070249 O.20032280 O.20042365 O.20737027 O.22095645 O.31241813 O.50070584 SRPT http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html <p> – <b><i>Severino joins Sarepta’s Board of Directors</i></b> </p><p> – <b><i>Doug Ingram to retire from Sarepta</i></b> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition. </p><p> Severino brings more than 25 years of biopharmaceutical experience to Sarepta. Prior to http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html Mon, 27 Jul 2026 08:30:00 -0400 A.06145069 A.08435063 A.26342942 A.35954321 A.40221050 A.50216958 O.00070249 O.20032280 O.20042365 O.20737027 O.22095645 O.31241813 O.50070584 SRPT http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html <p> – <b><i>Severino joins Sarepta’s Board of Directors</i></b> </p><p> – <b><i>Doug Ingram to retire from Sarepta</i></b> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition. </p><p> Severino brings more than 25 years of biopharmaceutical experience to Sarepta. Prior to http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html Mon, 27 Jul 2026 08:30:00 -0400 A.06145069 A.08435063 A.26342942 A.35954321 A.40221050 A.50216958 O.00070249 O.20032280 O.20042365 O.20737027 O.22095645 O.31241813 O.50070584 SRPT http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html <p> – <b><i>Severino joins Sarepta’s Board of Directors</i></b> </p><p> – <b><i>Doug Ingram to retire from Sarepta</i></b> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition. </p><p> Severino brings more than 25 years of biopharmaceutical experience to Sarepta. Prior to http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html Mon, 27 Jul 2026 08:30:00 -0400 A.06145069 A.08435063 A.26342942 A.35954321 A.40221050 A.50216958 O.00070249 O.20032280 O.20042365 O.20737027 O.22095645 O.31241813 O.50070584 SRPT http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html <p> – <b><i>Severino joins Sarepta’s Board of Directors</i></b> </p><p> – <b><i>Doug Ingram to retire from Sarepta</i></b> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition. </p><p> Severino brings more than 25 years of biopharmaceutical experience to Sarepta. Prior to http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html Mon, 27 Jul 2026 08:30:00 -0400 A.06145069 A.08435063 A.26342942 A.35954321 A.40221050 A.50216958 O.00070249 O.20032280 O.20042365 O.20737027 O.22095645 O.31241813 O.50070584 SRPT http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html <p> – <b><i>Severino joins Sarepta’s Board of Directors</i></b> </p><p> – <b><i>Doug Ingram to retire from Sarepta</i></b> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition. </p><p> Severino brings more than 25 years of biopharmaceutical experience to Sarepta. Prior to http://www.streetinsider.com/Press+Releases/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html Mon, 27 Jul 2026 08:30:00 -0400 A.06145069 A.08435063 A.26342942 A.35954321 A.40221050 A.50216958 O.00070249 O.20032280 O.20042365 O.20737027 O.22095645 O.31241813 O.50070584 SRPT http://www.streetinsider.com/Business+Wire/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html <p> – <b><i>Severino joins Sarepta’s Board of Directors</i></b> </p><p> – <b><i>Doug Ingram to retire from Sarepta</i></b> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition. </p><p> Severino brings more than 25 years of biopharmaceutical experience to Sarepta. Prior to http://www.streetinsider.com/Business+Wire/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html Mon, 27 Jul 2026 08:30:00 -0400 A.06145069 A.08435063 A.26342942 A.35954321 A.40221050 A.50216958 O.00070249 O.20032280 O.20042365 O.20737027 O.22095645 O.31241813 O.50070584 SRPT http://www.streetinsider.com/Business+Wire/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html <p> – <b><i>Severino joins Sarepta’s Board of Directors</i></b> </p><p> – <b><i>Doug Ingram to retire from Sarepta</i></b> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition. </p><p> Severino brings more than 25 years of biopharmaceutical experience to Sarepta. Prior to http://www.streetinsider.com/Business+Wire/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html Mon, 27 Jul 2026 08:30:00 -0400 A.06145069 A.08435063 A.26342942 A.35954321 A.40221050 A.50216958 O.00070249 O.20032280 O.20042365 O.20737027 O.22095645 O.31241813 O.50070584 SRPT http://www.streetinsider.com/Business+Wire/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html <p> – <b><i>Severino joins Sarepta’s Board of Directors</i></b> </p><p> – <b><i>Doug Ingram to retire from Sarepta</i></b> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition. </p><p> Severino brings more than 25 years of biopharmaceutical experience to Sarepta. Prior to http://www.streetinsider.com/Business+Wire/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html Mon, 27 Jul 2026 08:30:00 -0400 A.06145069 A.08435063 A.26342942 A.35954321 A.40221050 A.50216958 O.00070249 O.20032280 O.20042365 O.20737027 O.22095645 O.31241813 O.50070584 SRPT http://www.streetinsider.com/Business+Wire/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html <p> – <b><i>Severino joins Sarepta’s Board of Directors</i></b> </p><p> – <b><i>Doug Ingram to retire from Sarepta</i></b> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition. </p><p> Severino brings more than 25 years of biopharmaceutical experience to Sarepta. Prior to http://www.streetinsider.com/Business+Wire/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html Mon, 27 Jul 2026 08:30:00 -0400 A.06145069 A.08435063 A.26342942 A.35954321 A.40221050 A.50216958 O.00070249 O.20032280 O.20042365 O.20737027 O.22095645 O.31241813 O.50070584 SRPT http://www.streetinsider.com/Business+Wire/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html <p> – <b><i>Severino joins Sarepta’s Board of Directors</i></b> </p><p> – <b><i>Doug Ingram to retire from Sarepta</i></b> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition. </p><p> Severino brings more than 25 years of biopharmaceutical experience to Sarepta. Prior to http://www.streetinsider.com/Business+Wire/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html Mon, 27 Jul 2026 08:30:00 -0400 A.06145069 A.08435063 A.26342942 A.35954321 A.40221050 A.50216958 O.00070249 O.20032280 O.20042365 O.20737027 O.22095645 O.31241813 O.50070584 SRPT http://www.streetinsider.com/Business+Wire/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html <p> – <b><i>Severino joins Sarepta’s Board of Directors</i></b> </p><p> – <b><i>Doug Ingram to retire from Sarepta</i></b> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition. </p><p> Severino brings more than 25 years of biopharmaceutical experience to Sarepta. Prior to http://www.streetinsider.com/Business+Wire/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html Mon, 27 Jul 2026 08:30:00 -0400 A.06145069 A.08435063 A.26342942 A.35954321 A.40221050 A.50216958 O.00070249 O.20032280 O.20042365 O.20737027 O.22095645 O.31241813 O.50070584 SRPT http://www.streetinsider.com/Business+Wire/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html <p> – <b><i>Severino joins Sarepta’s Board of Directors</i></b> </p><p> – <b><i>Doug Ingram to retire from Sarepta</i></b> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition. </p><p> Severino brings more than 25 years of biopharmaceutical experience to Sarepta. Prior to http://www.streetinsider.com/Business+Wire/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html Mon, 27 Jul 2026 08:30:00 -0400 A.06145069 A.08435063 A.26342942 A.35954321 A.40221050 A.50216958 O.00070249 O.20032280 O.20042365 O.20737027 O.22095645 O.31241813 O.50070584 SRPT http://www.streetinsider.com/Business+Wire/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html <p> – <b><i>Severino joins Sarepta’s Board of Directors</i></b> </p><p> – <b><i>Doug Ingram to retire from Sarepta</i></b> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition. </p><p> Severino brings more than 25 years of biopharmaceutical experience to Sarepta. Prior to http://www.streetinsider.com/Business+Wire/Sarepta+Therapeutics+Appoints+Michael+Severino%2C+M.D.%2C+Chief+Executive+Officer/26816598.html Mon, 27 Jul 2026 08:30:00 -0400 A.06145069 A.08435063 A.26342942 A.35954321 A.40221050 A.50216958 O.00070249 O.20032280 O.20042365 O.20737027 O.22095645 O.31241813 O.50070584 SRPT